Evidence map›Paper›PMID 29126195›Full record

ReviewFEMS microbiology reviews2018

Structural insights into simocyclinone as an antibiotic, effector ligand and substrate.

Mark J Buttner, Martin Schäfer, David M Lawson, Anthony Maxwell

Open access · bronzeAbstract readReview
In one paragraph

Review in FEMS microbiology reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Mark J ButtnerDepartment of Molecular Microbiology, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK.
Martin SchäferDepartment of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.
David M LawsonDepartment of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK.
Anthony MaxwellDepartment of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK.
John Innes Centre · GBDuke University · US

Funding

Biotechnology and Biological Sciences Research Council BB/I002049/1Biotechnology and Biological Sciences Research Council BB/I002197/1Biotechnology and Biological Sciences Research Council BB/J004561/1Biotechnology and Biological Sciences Research Council BBS/E/J/00000015Biotechnology and Biological Sciences Research Council BBS/E/J/00000201
6 · The paper itself

Abstract

Simocyclinones are antibiotics produced by Streptomyces and Kitasatospora species that inhibit the validated drug target DNA gyrase in a unique way, and they are thus of therapeutic interest. Structural approaches have revealed their mode of action, the inducible-efflux mechanism in the producing organism, and given insight into one step in their biosynthesis. The crystal structures of simocyclinones bound to their target (gyrase), the transcriptional repressor SimR and the biosynthetic enzyme SimC7 reveal fascinating insight into how molecular recognition is achieved with these three unrelated proteins.

Indexed as

Anti-Bacterial AgentsDNA GyraseEnzyme ActivationGlycosidesLigandsAnti-Bacterial AgentsDNA GyraseGlycosidesLigandsaminocoumarinsantibioticsDNA gyraseDNA topoisomerasesStreptomycestranscription factor

Identifiers

PMID29126195
PMCPMC5812520
OpenAlexW2767500852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.